Because both tumor-infiltrating lymphocyte enrichment [24] and PD-L1 expression [25] are positive predictors for anti-PD-1/PD-L1/CTLA-4 immunotherapy response and DEPTH2 scores likely correlated negatively with both of them, we anticipated that the tumors with high DEPTH2 ITH would respond worse to immune checkpoint inhibitors (ICIs) versus the tumors with low DEPTH2 ITH. This evidence concerns the gene CTLA4 and neoplasm.